Novo Nordisk's oral Wegovy pill is moving at roughly two hundred thousand prescriptions a week and has now crossed two million dispensed scripts in sixteen weeks on the market, according to the IQVIA tracker FiercePharma maintains and which both companies cite on earnings calls. [1] Eli Lilly's oral Foundayo, launched in the same category three months later, posted 7,335 prescriptions in its fourth full week. [2] The two numbers belong to the same physician panel and the same payer architecture. They are not two outcomes of one race. They are two outcomes of two different races that the analyst community is still struggling to price separately.

The paper's Saturday account named the 24x gap as the structural read on whether GLP-1 economics deliver to Lilly and Novo equity holders or compress into a populist cheap-treatment regime. The companion brief held RBC Capital Markets' week-12 bar at ninety thousand scripts as the line below which Lilly's $1 billion fiscal-year consensus model breaks. Today, that line is not where the analyst spread is anchored. BMO Capital Markets' "twelve percent below consensus" flag — the most bearish of the major sell-side estimates as of late April — is now sitting near the middle of the published estimate range, not at its edge.

The volume side

Novo's chief executive Maziar Mike Doustdar described the company's pricing posture on the Q1 call as targeting "the sweet spot — the price where the volume builds and the gross dollars build with it." [3] The shape of the volume curve is the case for the strategy. Wegovy oral was at three thousand scripts in its first four days, eighteen thousand four hundred ten in its second week, and is now at roughly two hundred thousand a week sixteen weeks in. The compound trajectory is what Novo's call language is built around. The company reaffirmed full-year guidance and did not flag any deceleration of Wegovy oral scripts inside its commentary.

Doustdar's number is built on $149 a month at retail for the starter dose, which is the price most patients pay at the pharmacy counter before they progress to higher-dose tiers. The Q1 segment print was $355 million from the oral pill alone — a number that is small inside Novo's overall Wegovy franchise but is, internally, the metric the company uses to forecast whether the oral pill will displace injectable Wegovy on its own demand curve.

The dollar side

Lilly's Foundayo is the same molecule class (oral GLP-1 receptor agonist) and a different price point. The starter dose is similar at retail. The volume curve, however, is materially flatter. Foundayo was at 1,390 scripts in Week 1, near four thousand in Week 2, and at 7,335 in Week 4. The RBC Capital Markets bar — ninety thousand scripts in week twelve — is the line below which Lilly's published guidance of roughly one billion dollars in Foundayo revenue for fiscal 2026 stops being achievable on a linear trajectory. The Week 4 print is on a curve that does not produce ninety thousand in week twelve.

BMO's note last month, which carried a $735 price target on Lilly against the Street's mid-$800s consensus, was built on the assumption that cheap starter doses would dominate the Foundayo mix while higher-dose tiers under-converted. The note was the outlier. Today it sits near the middle of a tightening estimate distribution as more banks step into the same volume-dollar split. Citigroup added a complicating layer last week: a research note arguing that IQVIA's panel likely understates Foundayo's telehealth share, on the theory that a meaningful slice of the molecule is dispensed through direct-to-consumer telehealth platforms that IQVIA's retail panel undercounts.

If the Citigroup adjustment is right, the Foundayo Week 4 print at 7,335 may be closer to nine or ten thousand on a true-share basis. That is the same compounding shape Wegovy ran, just at one-eighteenth the cadence. The shape is structural; the slope is the question.

What the split actually means

The numbers are not telling two stories of one race. They are telling one story of the GLP-1 oral category at this price point. The molecule sells at the starter dose; the patient does not progress to the higher-dose tier at the rate the original financial models assumed; and the dollar print compresses against a volume base that is, on its own, an undeniable public-health phenomenon. Wegovy oral at two million scripts in four months is, in absolute terms, one of the fastest commercial-pharmaceutical launches in living memory.

The split, in the analyst community, is between two reads of what that means for equity holders. The Novo read — Doustdar's "sweet spot" — is that the volume curve will, in time, pull the dollar curve with it, because patients who tolerate the starter dose stay on the starter dose for a long time. The Lilly read — the one BMO is now near the consensus on — is that the volume-dollar gap is a structural property of the molecule's competitive landscape at this price point, and that the gross dollar number compresses against an analyst model that assumed dose-tier ladders the patient is not climbing.

A category that, at peak volume, runs at one-eighteenth the dollar conversion of the projected model is, in financial terms, a different category. It is also, in clinical terms, a public-health intervention. Public-health interventions and equity stories rarely share a forward-quarter cadence.

The cross-cut

The volume-dollar split inside Foundayo is a particular case of a more general pattern the paper has tracked inside the demographic-winter thread. The general pattern: consumer-ritual spending inflates while the demographic register compresses. Mother's Day spending hit $38 billion this weekend, a National Retail Federation record. [4] Total fertility rate, the U.S. third-quarter number, was 1.594. Infant daycare costs more than in-state four-year college tuition in thirty-three states. The arithmetic of the household is not the arithmetic of the analyst model.

GLP-1 prescription cadence at two hundred thousand a week is the same shape as Mother's Day at $38 billion. Both are robust volume curves. Both compress against the dollar models that were used to forecast them. Doustdar's "sweet spot" is a $149-a-month sweet spot. The American household budget is now built around it. Lilly's $1 billion full-year model was built before the household budget was. The model is the one that is moving.

-- NORA WHITFIELD, Chicago